<DOC>
	<DOC>NCT00641225</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of single doses of SBI-087 in subjects with rheumatoid arthritis.</brief_summary>
	<brief_title>Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Man or nonlactating and nonpregnant woman, aged 18 to 70 years, inclusive, at the screening visit. Must meet criteria for rheumatoid arthritis with functional class I to III. Diagnosis of rheumatoid arthritis more than 6 months before study day 1 and rheumatoid arthritis onset after 16 years of age Any significant health problems other than rheumatoid arthritis. Treatment of greater than 10 mg of prednisone per day. Treatment with cyclophosphamide.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Ascending Single Dose</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Open-label</keyword>
</DOC>